MedTrace Logo

Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

NCT07258147 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-05

No results posted yet for this study

Summary

This is clinical trial evaluating the safety and efficacy of radiotherapy combined with immunotherapy and chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) and liver metastases.

Conditions

  • Lung Cancer (SCLC)

Interventions

DRUG

Immunotherapy

Combined With Chemotherapy( (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin) ). Liver-directed radiotherapy (low-dose radiation(3Gy\*5d) or low-dose radiation(3Gy\*5d) +stereotactic body radiation therapy (10Gy\*3d) ) followed by Immunotherapy

DRUG

Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin)

Combined With immunotherapy.

RADIATION

low-dose radiation

Liver-directed radiotherapy (low-dose radiation(3Gy\*5d) followed by Immunotherapy

RADIATION

Stereotactic Body Radiation Therapy (SBRT)

low-dose radiation(3Gy\*5d) +stereotactic body radiation therapy (10Gy\*3d) )

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • You Lu · Principal Investigator

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-31
Primary Completion
2027-12-31
Completion
2028-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07258147 on ClinicalTrials.gov